Key facts
- Biomemory’s last known valuation is $38.5M.
- It has raised $23.4M; the latest was Early Stage VC ($18.0M) in Nov 2024.
- Notable investors include Bpifrance, Agoranov, Crédit Mutuel Equity, AH Capital, ADNEXUS (Paris) — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Biomemory
- ·The full record, as it builds
Funding rounds
No funding rounds for Biomemory are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biomemory
Developer of data storage drives designed to offer bio-digital data storage for large companies and administrations. The company's drives are low-cost and have a biobased system for storing large amounts of computer data on long DNA strands than any SSD or magnetic tape that is stable at ambient temperature with no energetic input and CO2 emission, enabling researchers to get ultimate storage media durable for thousands of years.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2021
- Employees
- 33
- Website
- biomemory.com/
- Ownership
- Privately Held (backing)
Biomemory doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biomemory shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biomemory in its N-PORT filings yet. We sweep new filings monthly.